LABORATORY RESEARCH MicroRNA (miR)-24 Enhances Tumor Invasion and Metastasis by Targeting PTPN9 and PTPRF to Promote EGF Signaling Scientists analyzed miR-24 levels in patients with breast carcinoma and found that miR-24 was higher in breast carcinoma samples than in breast benign tissues. They generated constructs expressing miR-24 and studied its functions using both in vitro and in vivo techniques. [J Cell Sci] Abstract cGMP-Dependent Protein Kinase Iβ Regulates Breast Cancer Cell Migration and Invasion via a Novel Interaction with the Actin/Myosin-Associated Protein Caldesmon Using the type I cGMP-dependent protein kinase β isoform (PKGIβ) dimerization domain as an affinity probe in a proteomic screen, the authors identified the actin/myosin-associated protein caldesmon (CaD) as a PKGIβ-specific binding protein. PKGIβ phosphorylated human CaD on serine 12 in vitro and in intact cells. [J Cell Sci] Abstract Vimentin, Zeb1 and Sip1 Are Up-Regulated in Triple-Negative and Basal-Like Breast Cancers: Association with an Aggressive Tumor Phenotype Scientists assessed immunohistochemically vimentin as an indicator of epithelial-to-mesenchymal transition (EMT), and also EMT-regulating transcription factors zeb1 and Sip1 in histological samples of 231 women with local or locally advanced invasive breast cancer. [Breast Cancer Res Treat] Abstract Critical Role for Reactive Oxygen Species in Apoptosis Induction and Cell Migration Inhibition by Diallyl Trisulfide, a Cancer Chemopreventive Component of Garlic Exposure of human breast cancer cells and a cell line derived from spontaneously developing mammary tumor of a transgenic mouse to diallyl trisulfide resulted in a dose-dependent inhibition of cell viability that was accompanied by apoptosis induction. [Breast Cancer Res Treat] Abstract Invadopodia-Associated Proteins Blockade as a Novel Mechanism for 6-Shogaol and Pterostilbene to Reduce Breast Cancer Cell Motility and Invasion By wound-healing, transwell, and gelatin zymography assays, scientists found that 6-shogaol and pterostilbene effectively attenuated the motility and invasion of MDA-MB-231 cells, and suppressed the activities of matrix metalloproteinase-2 (MMP-2) and MMP-9. [Mol Nutr Food Res] Abstract Norspermidine and Novel Pd(II) and Pt(II) Polynuclear Complexes of Norspermidine as Potential Antineoplastic Agents against Breast Cancer The cytotoxic effects of a biogenic polyamine analogue – norspermidine – and its trinuclear Pd(II) and Pt(II) complexes – Pd3NSpd2 and Pt3NSpd2, respectively – were investigated in one immortalized normal-like and three breast cancer cell lines. [PLoS One] Full Article Separation by Cell Size Enriches for Mammary Stem Cell Repopulation Activity Cell sorting techniques for specific cell surface markers (CD24+CD29HCD49fHSca1–) have been used to prospectively isolate mammary stem cells (MaSC)-enriched populations. Although these markers enrich for cell subpopulations that harbor MaSCs, they do not identify regenerative stem cells uniquely. Researchers report that MaSCs can be further defined by the property of cell size. [Stem Cell Transl Med] Abstract CLINICAL RESEARCH Ganitumab with either Exemestane or Fulvestrant for Postmenopausal Women with Advanced, Hormone-Receptor-Positive Breast Cancer: A Randomized, Controlled, Double-Blind, Phase 2 Trial Insulin-like growth factors (IGF-1 and IGF-2) bind to the IGF-1 receptor (IGF-1R), increasing cell proliferation and survival. Ganitumab is a monoclonal IgG1 antibody that blocks IGF-1R. Researchers tested the efficacy and safety of adding ganitumab to endocrine treatment for patients with hormone-receptor-positive breast cancer. [Lancet Oncol] Abstract CNS Relapses in Patients with HER2-Positive Early Breast Cancer Who Have and Have Not Received Adjuvant Trastuzumab: A Retrospective Substudy of the HERA Trial Several randomized trials have confirmed the benefit of adjuvant trastuzumab for patients with HER2-positive early breast cancer. However, concern has been expressed that adjuvant trastuzumab might be associated with an increased frequency of CNS relapses. The authors assessed the frequency and course of CNS relapses, either as first event or at any time, using data from the HERA trial. [Lancet Oncol] Abstract |